Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Life Science Investing
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Life Science Investing
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update Life Science Investing
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Life Science Investing
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference Life Science Investing
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference Life Science Investing
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference Life Science Investing
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS Life Science Investing
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma Life Science Investing
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th Life Science Investing
